Skip to main content

Table 4 Univariate Logistic Regression models for relative risk of select individual treatment and toxicity related outcomes according to PI use

From: The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study

Outcome Taking a Protease Inhibitor
Odds Ratio (95% CI)
p-value
Treatment-related
 Completed Radiation 0.71 (0.27–1.86) 0.48
 Length of Radiation Treatment > 50 days 0.74 (0.40–1.36) 0.33
 Required a Chemotherapy Dose Reduction 1.47 (0.76–2.84) 0.25
Toxicities during treatment
 Hospitalized for GI Toxicity 1.01 (0.25–4.02) 0.99
 Hospitalized for Hematologic Toxicity 4.60 (1.56–13.5) < 0.01
 Hospitalized for Febrile Neutropenia 6.25 (1.44–27.2) 0.01
 Hospitalized for Radiation Dermatitis 0.74 (0.21–2.63) 0.65
 Acute Radiation Dermatitis at least Grade 3 0.94 (0.51–1.74) 0.85
 Acute GI Toxicity at least Grade 3 1.94 (0.70–5.39) 0.20
 Acute Oral Mucositis at least Grade 3 1.04 (0.35–3.07) 0.95
 Late GI Toxicity at least Grade 3 1.56 (0.49–4.93) 0.45
 Other Late Toxicity at least Grade 3 0.63 (0.17–2.32) 0.49
 Any Acute Hematologic Toxicity 2.12 (1.18–3.83) 0.01
 Acute Anemia at least Grade 3 1.47 (0.39–5.52) 0.57
 Acute Leukopenia at least Grade 3 1.73 (0.93–3.23) 0.08
 Acute Thrombocytopenia at least Grade 3 1.54 (0.71–3.34) 0.28
 Acute Neutropenia at least Grade 3 1.73 (0.71–4.20) 0.23
 Acute Lymphopenia at least Grade 3 1.92 (1.05–3.51) 0.03